The Half-Life Problem: Why Radiopharmaceutical Logistics Are Unlike Any Other Drug

In radiopharma, time isn’t just money. It’s physics.

For most investigational drugs, a shipment delay is an operational problem. For a radiopharmaceutical, delay can change the product itself.

From the moment a radionuclide is produced, radioactive decay is underway. Manufacturing, quality release, transportation, site receipt, patient preparation, and administration are therefore connected by a physical clock that clinical operations cannot reset.

That fundamental difference makes radiopharmaceutical logistics part of the clinical development strategy. As pipelines expand and trials reach broader site networks, sponsors need supply chains designed around the isotope—not adapted from conventional drug development.

Half-Life Shapes the Development Model

Radionuclides vary substantially in their physical properties. Zhang et al. describe half-lives ranging from minutes to days across radionuclides used in medicine: gallium-68 has a half-life of approximately 68 minutes, fluorine-18 approximately 110 minutes, lead-212 approximately 10.6 hours, and lutetium-177 approximately 6.65 days.[1]  

Those differences have immediate operational consequences.

A short-lived imaging isotope may require production close to the clinical site and tightly synchronized imaging schedules. A longer-lived therapeutic radionuclide can support broader distribution, but still requires coordinated manufacturing, release, shipment, storage, preparation, and administration.

The isotope effectively defines the boundaries within which the supply chain must operate.

This is why radiopharmaceutical half life logistics should be considered early in development. Radionuclide selection influences more than biological performance. It can affect manufacturing strategy, site geography, treatment scheduling, scalability, and ultimately which patients can realistically participate.

The Dose Is Moving While the Clock Is Running

Traditional drug supply chains are generally designed to protect product quality between manufacturing and administration. Radiopharmaceutical supply chains must do that while accounting for continuously changing radioactivity.

Every handoff matters.

Production must align with quality control and release. Transportation must align with the site's treatment schedule. Site readiness must align with patient readiness. The administered activity must meet protocol requirements at the intended administration time.

A disruption at one point can propagate through the entire workflow.

Weather, transportation delays, manufacturing interruptions, equipment availability, or a patient who cannot receive treatment as scheduled may create consequences that extend beyond rescheduling an appointment. Depending on the radionuclide and protocol, the product may no longer be suitable for its intended use.

Theragnostic Insight: For radiopharmaceutical trials, logistics should be mapped as a clinical workflow rather than treated as a standalone supply-chain function. The critical pathway runs from isotope production all the way to patient administration.

Isotope Decay Changes Site Strategy

These constraints become even more important as sponsors expand trials geographically.

Zhang et al. highlight how radionuclide half-life can directly affect distribution. Copper-64, for example, has a half-life of approximately 12.7 hours, which the authors identify as one characteristic that can facilitate transportation to more distant hospitals.[1]  

This relationship between isotope decay and drug delivery means site feasibility cannot be separated from supply-chain feasibility.

A site may have an experienced investigator, appropriate patients, and strong nuclear medicine capabilities yet still be difficult to support if the investigational product cannot reliably reach it within the required timeframe.

Sponsors therefore need to evaluate manufacturing location, transportation routes, delivery windows, site receiving capabilities, treatment schedules, and contingency options alongside conventional feasibility criteria.

The question is not simply, “Can this site run the study?”

It is, “Can the complete system reliably deliver this radiopharmaceutical to this patient at this site, cycle after cycle?”

Resilience Has to Be Designed In

A tightly controlled timeline does not leave much room for improvisation.

Radiopharma supply chain planning should anticipate foreseeable disruptions before enrollment begins. That includes defining communication pathways when production or transportation is delayed, clarifying dose acceptance criteria, coordinating patient scheduling with delivery windows, and establishing decision points for rescheduling or replacement.

The operational plan also needs to reflect the specific radionuclide. A model developed for a longer-lived beta-emitter cannot automatically be transferred to a short-lived imaging agent or an emerging alpha-emitting therapy.

As Zhang et al. note, radionuclides differ in half-life, decay mode, radiation energy, production method, and clinical application.[1] Those scientific properties translate directly into different operational requirements.

What This Means for You

Radiopharmaceutical development forces clinical teams to think differently about time.

Manufacturing, supply chain, site operations, and patient scheduling cannot function as loosely connected workstreams. They are components of one time-dependent clinical system.

For biotech and pharma teams, that means incorporating radiopharmaceutical logistics into protocol development and site strategy early—not after sites are selected. For clinical sites, it means building workflows capable of coordinating product receipt, nuclear medicine resources, staff, facilities, and patients with precision.

Theragnostic Insights helps development teams translate isotope characteristics into practical clinical strategies—from site feasibility and workflow design to operational readiness and execution.

Because in radiopharma, the clock starts long before the patient enters the treatment room.

References

[1] Zhang S, Wang X, Gao X, et al., 2025. Radiopharmaceuticals and their applications in medicine. Signal Transduction and Targeted Therapy, 10:1.  

[2] U.S. Food and Drug Administration. Current Good Manufacturing Practice for Positron Emission Tomography Drugs. FDA Guidance for Industry.

[3] U.S. Nuclear Regulatory Commission. Medical Use of Byproduct Material. 10 CFR Part 35.

‍